Gabriel Cerrone files SEC Form 4 disclosures for SYNERGY PHARMACEUTICALS, INC.. They have made 12 open-market trades across 2 companies since 2011, most recently 2013-10-29.
CIK 0001253803
Unrated. We grade insiders only on stock they chose to buy on the open market. Grants, option exercises and vesting say nothing about timing, so they don't count — which is why someone can file often and still have no grade. It isn't a bad sign: unrated buys beat every graded tier below A.
12 open-market purchases totalling $1.9M since 2011, never a sale. Across 9 scored buys the stock is down 3.9% at ninety days, and 4.2 points behind the S&P over the same stretch.
9 scored purchases · one row per filing · discretionary only
| 7d | 30d | 90d | |
|---|---|---|---|
| Accuracy | 0% | 0% | 0% |
| Avg Move | -28.4% | -3.9% | -3.9% |
| Alpha | -22.6% | -4.2% | -4.2% |
| Scored | 9 | 9 | 9 |
| Ticker | Type | Traded | Filed | Price | Value | 7d Stock | 30d Stock | 90d Stock |
|---|---|---|---|---|---|---|---|---|
| SGYP | BUY | 2013-10-29 | 2013-10-29 | $4.09 | $49K | -28.4% | -3.9% | -3.9% |
| SGYP | BUY | 2013-06-14 | 2013-06-14 | $4.42 | $35K | -28.4% | -3.9% | -3.9% |
| SGYP | BUY | 2013-04-24 | 2013-04-24 | $4.46 | $56K | -28.4% | -3.9% | -3.9% |
| SGYP | BUY | 2013-04-24 | 2013-04-24 | $4.66 | $26K | -28.4% | -3.9% | -3.9% |
| SGYP | BUY | 2013-02-04 | 2013-02-04 | $6.04 | $79K | -28.4% | -3.9% | -3.9% |
| SGYP | BUY | 2013-02-04 | 2013-02-05 | $6.15 | $31K | -28.4% | -3.9% | -3.9% |
| SGYP | BUY | 2013-01-30 | 2013-02-01 | $5.99 | $156K | -28.4% | -3.9% | -3.9% |
| SGYP | BUY | 2012-11-14 | 2012-11-15 | $3.61 | $317K | -28.4% | -3.9% | -3.9% |
| TROV | BUY | 2012-08-17 | 2012-08-20 | $2.35 | $18K | N/A | N/A | N/A |
| TROV | BUY | 2012-08-16 | 2012-08-17 | $2.24 | $34K | N/A | N/A | N/A |
| TROV | BUY | 2012-04-13 | 2012-04-16 | $0.50 | $100K | N/A | N/A | N/A |
| SGYP | BUY | 2011-11-14 | 2011-11-15 | $2.13 | $1.0M | -28.4% | -3.9% | -3.9% |
Grouped by shared companies and similar filing behaviour. This is a similarity measure, not a ranking or a performance signal.